Liminal BioSciences Inc.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Bruce Pritchard BA, CA, FIOD
- Full Time Employees
- 251
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 440 Armand-Frappier Boulevard Laval QC Canada H7V 4B4
- IPO Date
- Dec 18, 2009
- CIK
- 0001351172
- Website
- liminalbiosciences.com
- Similar Companies
- Business
- Liminal BioSciences Inc. is a development-stage biopharmaceutical company focused on discovering and developing novel and distinctive small molecule therapeutics that modulate G protein-coupled receptor (GPCR) pathways. The company designs proprietary small molecule therapeutic candidates aimed at developing best-in-class treatments for metabolic, inflammatory, and fibrotic diseases with significant unmet medical needs. Its core product candidates include LMNL6511, a selective antagonist for the GPR84 receptor, expected to enter Phase 1 clinical trials; LMNL6326, an antagonist for the OXER1 receptor targeting eosinophil-driven diseases; and GPR40 agonists, all in preclinical development. Liminal BioSciences operates primarily in Canada and the United Kingdom, with headquarters in Laval, Quebec, and was founded in 1994. Recently, Liminal BioSciences completed a going-private transaction through an arrangement agreement with Structured Alpha LP, a fund managed by Thomvest Asset Management Ltd., providing liquidity and strategic partnership benefits to the company. This transaction, completed in late 2023, supports the company’s continued focus on advancing its pipeline and exploring additional development opportunities. The company also announced clinical development milestones, such as the expected commencement of Phase 1 trials for LMNL6511 in the second half of 2023, marking a significant step in its product development. Additionally, Liminal BioSciences continues to leverage its drug discovery platform and medicinal chemistry expertise to advance novel therapies targeting complex diseases with unmet patient needs. Liminal BioSciences’ business segments concentrate on biopharmaceutical research and development, emphasizing small molecule medicines for rare and complex diseases. It serves global markets, focusing on patients with metabolic, inflammatory, and fibrotic disorders. Its wholly owned subsidiary, Caledon Bioscience Inc., supports its drug discovery and development efforts. The company’s approach integrates deep biological insights into GPCR pathways with a proprietary data-driven platform to create innovative therapeutic solutions. In summary, Liminal BioSciences engages in proprietary small molecule drug discovery and clinical development primarily for metabolic, inflammatory, and fibrotic diseases; it recently transitioned to private ownership under Structured Alpha LP and is advancing several clinical and preclinical candidates in North American and European markets. The company operates from Laval, Canada, with research hubs in the United Kingdom, maintaining a robust pipeline targeting diseases with high unmet medical needs using its focused expertise in GPCR biology and medicinal chemistry.
LIMINAL BIOSCIENCES ANNOUNCES COMPLETION OF THE PLAN OF ARRANGEMENT WITH STRUCTURED ALPHA LP
LIMINAL BIOSCIENCES RECEIVES FINAL COURT ORDER FOR PLAN OF ARRANGEMENT WITH STRUCTURED ALPHA LP
LIMINAL BIOSCIENCES SHAREHOLDERS APPROVE PLAN OF ARRANGEMENT WITH STRUCTURED ALPHA LP
LIMINAL BIOSCIENCES FILES AMENDED SCHEDULE 13E-3 AND SUPPLEMENT TO THE MANAGEMENT INFORMATION CIRCULAR
LIMINAL BIOSCIENCES OBTAINS INTERIM ORDER FOR PROPOSED ARRANGEMENT WITH STRUCTURED ALPHA LP
Liminal (LMNL) Up 40% on Buyout Offer From Majority Shareholder
Liminal BioSciences stock rockets on take-private deal with a fund managed by Thomvest Asset Management
Liminal BioSciences Announces Arrangement Agreement with Structured Alpha LP
Why Is Liminal Biosciences (LMNL) Stock Up 77% Today?
Liminal Biosciences' stock soars 91% after getting takeover offer that's more than double its price
Liminal BioSciences Inc. (LMNL) Q4 2022 Earnings Call Transcript
Liminal BioSciences to Present at BIO CEO & Investor Conference
Liminal Biosciences (LMNL) Q3 2022 Earnings Call Transcript
Liminal BioSciences Reports Second Quarter 2022 Financial Results and Business Highlights
Liminal BioSciences Inc. (LMNL) CEO Bruce Pritchard on Q1 2022 Results - Earnings Call Transcript
Liminal Biosciences to Present at Upcoming Investor Conferences
Liminal BioSciences Pauses Development Of Fezagepras, Outlines R&D Priorities For 2022
Liminal BioSciences Announces Closing of Sale of Remaining Plasma-Derived Therapeutics Business
Liminal BioSciences Announces Closing of Sale of Priority Review Voucher
Liminal BioSciences Inc. (LMNL) CEO Bruce Pritchard on Q2 2021 Results - Earnings Call Transcript